$
73.700
+0.78(1.070%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
73.700
Open
73.700
VWAP
73.70
Vol
6.86K
Mkt Cap
12.62B
Low
73.700
Amount
505.43K
EV/EBITDA(TTM)
14.57
Total Shares
173.01M
EV
20.06B
EV/OCF(TTM)
25.98
P/S(TTM)
1.54
Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverages deep material science, data science, and digital capabilities to address customer and patient needs. The Company's segments include MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. MedSurg segment provides solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, and others. Dental Solutions segment provides a suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. Health Information Systems segment provides healthcare systems with software solutions, including computer-assisted physician documentation, direct-to-bill and coding automation, and data visualization platforms. Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
2.13B
+2.49%
1.411
+0.09%
2.11B
+1.31%
1.375
-16.16%
2.12B
+1.84%
1.450
-7.05%
Estimates Revision
The market is revising Upward the revenue expectations for Solventum Corporation (SOLV) for FY2025, with the revenue forecasts being adjusted by 1.82% over the past three months. During the same period, the stock price has changed by 11.84%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.82%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.41%
In Past 3 Month
Stock Price
Go Up
up Image
+11.84%
In Past 3 Month
8 Analyst Rating
up Image
14.21% Upside
Wall Street analysts forecast SOLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOLV is 84.17 USD with a low forecast of 75.00 USD and a high forecast of 90.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
5 Hold
0 Sell
Moderate Buy
up Image
14.21% Upside
Current: 73.700
sliders
Low
75.00
Averages
84.17
High
90.00
Morgan Stanley
Patrick Wood
Equal Weight -> Overweight
upgrade
$80 -> $103
2025-07-15
Reason
Morgan Stanley analyst Patrick Wood upgraded Solventum to Overweight from Equal Weight with a price target of $103, up from $80. The firm has increased confidence in Solventum hitting the mid-point of the 2028 guidance, suggesting EPS nearing $9 by that point along with essentially a cash neutral balance sheet, the analyst tells investors in a research note.
Argus
Hold
to
Buy
upgrade
$90
2025-07-01
Reason
Argus upgraded Solventum to Buy from Hold with a $90 price target.
Argus
David Toung
Hold
to
Buy
upgrade
$90
2025-07-01
Reason
Argus analyst David Toung upgraded Solventum (SOLV) to Buy from Hold with a $90 price target. The company has registered sequential topline growth over the past few quarters and showed earnings power with its Q1 results, the analyst tells investors in a research note. While there is still considerable work to restructure and reposition the company after its separation from 3M (MMM), Solventum has transformed into a faster-growing and higher-margin business model under the leadership of CEO Bryan Hanson, Argus added.
KeyBanc
Sector Weight
initiated
2025-06-06
Reason
Piper Sandler
Neutral -> Overweight
upgrade
$78 -> $87
2025-05-19
Reason
Piper Sandler
Jason Bednar
Overweight
maintain
$80 -> $78
2025-05-09
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on Solventum to $78 from $80 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that included a healthy revenue beat. Management passed through the top-line upside with a 50bp raise to full year organic growth guidance, while EPS guidance is unchanged as the Q1 operational beat and tailwinds from recent Fx moves are fully absorbing 35c-45c in tariff headwinds, Piper adds.

Valuation Metrics

The current forward P/E ratio for Solventum Corp (SOLV.N) is 12.83, compared to its 5-year average forward P/E of 12.29. For a more detailed relative valuation and DCF analysis to assess Solventum Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
12.29
Current PE
12.83
Overvalued PE
13.59
Undervalued PE
10.99

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
9.03
Current EV/EBITDA
9.52
Overvalued EV/EBITDA
10.35
Undervalued EV/EBITDA
7.72

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.41
Current PS
1.47
Overvalued PS
1.56
Undervalued PS
1.27

Financials

Annual
Quarterly
FY2025Q1
YoY :
+2.68%
2.07B
Total Revenue
FY2025Q1
YoY :
-55.38%
170.00M
Operating Profit
FY2025Q1
YoY :
-42.19%
137.00M
Net Income after Tax
FY2025Q1
YoY :
-43.07%
0.78
EPS - Diluted
FY2025Q1
YoY :
-123.53%
-80.00M
Free Cash Flow
FY2025Q1
YoY :
-6.59%
54.30
Gross Profit Margin - %
FY2025Q1
YoY :
-75.03%
4.63
FCF Margin - %
FY2025Q1
YoY :
-43.71%
6.62
Net Margin - %
FY2025Q1
8.70
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.3M
Volume
6
6-9
Months
775.3K
Volume
7
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
4.6M
Volume
Months
6-9
6
2.7M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.0K
USD
1
6-9
Months
16.0K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

SOLV News & Events

Events Timeline

2025-05-09 (ET)
2025-05-09
09:55:01
Early notable gainers among liquid option names on May 9th
select
2025-05-08 (ET)
2025-05-08
16:24:37
Solventum sees FY25 adjusted EPS $5.45-$5.65, consensus $5.54
select
2025-05-08
16:23:42
Solventum reports Q1 adjusted EPS $1.34, consensus $1.22
select
Sign Up For More Events

News

9.5
07-17PRnewswire
Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025
4.0
07-01Benzinga
Argus Research Upgrades Solventum to Buy
2.0
06-18Newsfilter
Solventum Named a Best Company to Work for by U.S. News & World Report
Sign Up For More News

FAQ

arrow icon

What is Solventum Corp (SOLV) stock price today?

The current price of SOLV is 73.7 USD — it has increased 1.07 % in the last trading day.

arrow icon

What is Solventum Corp (SOLV)'s business?

arrow icon

What is the price predicton of SOLV Stock?

arrow icon

What is Solventum Corp (SOLV)'s revenue for the last quarter?

arrow icon

What is Solventum Corp (SOLV)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Solventum Corp (SOLV)'s fundamentals?

arrow icon

How many employees does Solventum Corp (SOLV). have?

arrow icon

What is Solventum Corp (SOLV) market cap?